Yumanity Therapeutics Inc... (YMTX)
Company Description
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.
Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein.
The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders.
Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Feb 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | n/a |
Contact Details
Address: 40 Guest Street Boston, Massachusetts United States | |
| Website | https://www.yumanity.com |
Stock Details
| Ticker Symbol | YMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001445283 |
| CUSIP Number | 98872L102 |
| ISIN Number | US98872L1026 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard Peters M.D., Ph.D. | Chief Executive Officer, Pres & Director |
| Michael D. Wyzga | SVice President, Chief Financial Officer & Treasurer |
| Chee Yeun Chung Ph.D. | Scientific Co-Founder & Associate Director of Discovery Biology |
| Devin Whittemore Smith | SVice President, Gen. Counsel & Sec. |
| Dr. Vikram Khurana M.D., Ph.D. | Scientific Co-Founder & Senior Advisor of Discovery Biology |
| Marie Epstein CPA | Vice President of Fin. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | 425 | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 10-K | Annual Report |
| Feb 10, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 25, 2024 | DEFA14A | Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 8-K | Current Report |